作者: Junichi Yamamoto , Nathalie Toublanc , Yuji Kumagai , Armel Stockis
DOI: 10.1007/S40261-014-0237-7
关键词:
摘要: Background and Objective The anti-epileptic drug levetiracetam is excreted renally. The objective of this trial was to evaluate the pharmacokinetics in Japanese patients with renal impairment including end-stage disease (ESRD) confirm that existing dosing instructions—based on data from European patients—are appropriate a population.